Download PDF
Thromb Haemost 2000; 84(02): 286-290
DOI: 10.1055/s-0037-1614009
Review Article
Schattauer GmbH

Activity of a Sub-cutaneously Administered Novel Mixed Micellar Formulation of Argatroban in Rat and Rabbit Models of Venous Thrombosis

Christopher N. Berry
1   From the Thrombosis and Haematology Section, Cardiovascular Thrombosis Department, Sanofi∼Synthelabo, Chilly Mazarin, France
,
Catherine Visconte
1   From the Thrombosis and Haematology Section, Cardiovascular Thrombosis Department, Sanofi∼Synthelabo, Chilly Mazarin, France
,
Catherine Lecoffre
1   From the Thrombosis and Haematology Section, Cardiovascular Thrombosis Department, Sanofi∼Synthelabo, Chilly Mazarin, France
,
Sylvette Lochot
1   From the Thrombosis and Haematology Section, Cardiovascular Thrombosis Department, Sanofi∼Synthelabo, Chilly Mazarin, France
,
Denise Girard
1   From the Thrombosis and Haematology Section, Cardiovascular Thrombosis Department, Sanofi∼Synthelabo, Chilly Mazarin, France
› Author Affiliations
Further Information

Publication History

Received 11 November 1999

Accepted after revision 02 March 2000

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

Summary

We studied the antithrombotic activity of a mixed micellar formulation containing 14 mg/ml argatroban administered by the subcutaneous (s. c.) route in rat and rabbit models of venous thrombosis. The effects on bleeding time in the rat tail transection bleeding time test were also studied. In a tissue factor-dependent arterio-venous shunt model, argatroban treatment led to dose-dependent reduction in thrombus weight with an estimated ID50 of 1.8 mg/kg s. c. In the same model, heparin had an estimated ID50 of 179 IU/kg. The antithrombotic activity of argatroban was accompanied by increases in the thrombin and ecarin clotting times but not the aPTT, whereas heparin increased the thrombin time and aPTT but not the ecarin clotting times. Argatroban also inhibited thrombus formation in a rabbit model of thromboplastin + stasis induced thrombosis in the rabbit jugular vein with an estimated ID50 of 1 mg/kg s. c. When tested in the rat tail transection bleeding time test, the mixed micellar formulation of argatroban caused significant increases in the bleeding time as from 8 mg/kg s. c., while heparin significantly increased the bleeding time at 800 U/kg. Mixed micellar argatroban appears to have a superior safety margin to heparin in terms of antithrombotic efficacy and bleeding risk.

Thus, a mixed micellar formulation of argatroban, which markedly enhances its solubility, could be useful as a potential antithrombotic agent for subcutaneous administration.

Keywords

Argatroban mixed micelles - rat venous thrombosis - rabbit venous thrombosis - tail-transection bleeding time
 

  • References

  • 1 Erikson BI, Ekman S, Kälebo P, Zachrisson BZ, Bach D, Close P. Prevention of deep-vein-thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-9.
    CrossrefPubMedGoogle Scholar
  • 2 Erikson BI, Mouret P, Kälebo P, Baue M, Ekman S, Lindbrat S, Bach D, Close P. Recombinant hirudin, CGP 39393 (Revasc), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement. Haemostasis 1996; 26 (Suppl. 03) 624.
    PubMedGoogle Scholar
  • 3 Okamoto S, Hijikata A, Kikumoto R, Tonomara S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-6.
    CrossrefPubMedGoogle Scholar
  • 4 Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, Hijikata A, Okamoto S. Selective inhibition of thrombin by (2R,4R)-4-Methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-arginyl]-2-piperidinecarboxylic acid. Biochemistry 1984; 23: 85-90.
    CrossrefPubMedGoogle Scholar
  • 5 Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72: 381-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Lunven C, Gauffeny C, Lecoffre C, O’Brien DP, Roome NO, Berry CN. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996; 75: 154-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Fujioka K. The Effect of MD-805 on Experimental Acute Arterial Thrombosis in Relation to Vasoactive Prostanoids (TXA2 and PGI2). J Jap Coll Angiol 1989; 29: 57-64.
    PubMedGoogle Scholar
  • 8 Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of Platelet-Rich Arterial Thrombosis by Selective Thrombin Inhibition. Circulation 1990; 81: 219-25.
    CrossrefPubMedGoogle Scholar
  • 9 Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, “mixed” and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994; 113: 1209-14.
    CrossrefPubMedGoogle Scholar
  • 10 Berry CN, Girard D, Girardot C, Lochot S, Lunven C, Visconte C. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Semin Thromb Hemost 1996; 22: 233-41.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Duval N, Lunven C, O’Brien DP, Grosset A, O’Connor SE, Berry CN. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin. Br J Pharmacol 1996; 118: 727-33.
    CrossrefPubMedGoogle Scholar
  • 12 Schumacher WA, Heran CL, Steinbacher TE. Low molecular weight heparin (Fragmin) and thrombin active site inhibitor (Argatroban) compared in experimental arterial thrombosis and bleeding time. J Cardiovascular Pharmacol 1996; 28: 19-25.
    CrossrefPubMedGoogle Scholar
  • 13 Berry CN, Lunven C, Girardot C, Lechaire I, Girard D, Charles M-C, Ferrari P, O’Brien DP. Ecarin clotting time: a predictive coagulation assay for the antithrombotic activity of argatroban in the rat. Thromb Haemost 1998; 79: 228-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Wessler S, Reimer SM, Sheps MC. Biologic assay of thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-6.
    CrossrefPubMedGoogle Scholar
  • 15 Berry CN, Lunven C, Lecoffre C, Lainée P, O’Connor SE, André F, Roger B, Garrigou-Gadenne D, Rouchouse A, Roome NO, Vivan N. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals. Thromb Haemost 2000; 84: 278-85.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Iida S, Komatsu T, Hirano T, Fujimura Y, Nakai H, Kitazawa K, Kumagai Y, Sato T, Hayashi K, Inokuchi K. Pharmacokinetic studies of argatroban (MD-805) in dogs and rabbits. Blood or plasma level profile, metabolism, excretion and accumulation after single or consecutive administration of argatroban. Oyo Yakuri (Pharmacometrics) 1986; 32: 1117-27.
    PubMedGoogle Scholar
  • 17 Clarke RJ, Mayo G, Fitzgerald GA, Fitzgerald DA. Combined administration of argatroban and aspirin in man. Circulation 1991; 83: 1510-9.
    CrossrefPubMedGoogle Scholar
  • 18 Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990; 40: 498-530.
    CrossrefPubMedGoogle Scholar
  • 19 Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, Berends F, Hammes WD, Rijnierse JJMM, Sturk A. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment. Thromb Haemost 1994; 72: 685-92.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Schwarz RP, Becker JCP, Brooks RL, Joffrion JL, Knappenberger GD, Kogan TP, Kogan PW, McKinney AA. The preclinical and clinical pharmacology of Novastan (argatroban): a small-molecule, direct thrombin inhibitor. Clin Appl Thrombos Hemost 1997; 03: 1-15.
    PubMedGoogle Scholar
  • 21 Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass – Assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77: 920-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Kher A, Al Dieri R, Hemker HC, Beguin S. Laboratory assessment of antithrombotic therapy: what tests and if so why?. Haemostasis 1997; 27: 211-8.
    PubMedGoogle Scholar
  • 23 Herrman JPR, Suryapranata H, den Heijer P, Gabriel L, Kutryk MJB, Serruys PW. Argatroban during percutaneous transluminal coronary angioplasty: results of a dose-verification study. J Thromb Thrombolys 1996; 03: 367-73.
    CrossrefPubMedGoogle Scholar
  • 24 Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114: 511S-523S.
    CrossrefPubMedGoogle Scholar